Anti CD19 targeting CAR T cell therapy in ANCA-associated vasculitis - PubMed
6 hours ago
- #ANCA-associated vasculitis
- #CAR T cell therapy
- #autoimmune disorders
- Successful case study of anti-CD19 CAR T cell therapy in a patient with relapsing granulomatosis with polyangiitis (GPA).
- 69-year-old male with refractory GPA underwent CD19-targeting CAR T cell therapy after failing standard treatments.
- Conditioning regimen included fludarabine and cyclophosphamide.
- Patient showed rapid improvement post-therapy with no cytokine release syndrome (CRS) or neurotoxicity.
- CAR T cells expanded transiently but were undetectable by day 90.
- Significant B cell depletion and hypogammaglobulinemia observed, with gradual recovery.
- Patient achieved complete remission without further medication at 12-month follow-up.
- CD19-targeted CAR T cell therapy was safe and effective for relapsed/refractory GPA.